India vs Indonesia: The number of people with susceptibility test result for rifampicin
India
673,008
in 2021
Indonesia
144,511
in 2021
India rank
1st
Indonesia rank
3rd
The number of people with susceptibility test result for rifampicin over time
- India
- Indonesia
How they compare
India currently reports 673,008 against 144,511 in Indonesia, a difference of 528,497.
That makes India's figure about 4.7 times Indonesia's.
Across all 5 years both countries report, India has been ahead every year.
India ranks 1st and Indonesia ranks 3rd of 155 countries.
India has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | India | Indonesia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 444,726 | 71,327 | 373,400 | India |
| 2020s | 615,232 | 121,178 | 494,054 | India |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, India or Indonesia?
- India, at 673,008 against 144,511 in Indonesia as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between India and Indonesia?
- 528,497, with India ahead.
- How many years of comparable data are there for India and Indonesia?
- 5 years are reported by both, from 2017 to 2021.
- How do India and Indonesia rank globally for the number of people with susceptibility test result for rifampicin?
- India ranks 1st and Indonesia ranks 3rd of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.